AHA Scientific Statement on Caffeine and Cardiovascular Disease

This AHA scientific statement synthesizes observational and emerging randomized evidence on caffeine and coffee across cardiovascular risk factors and diseases, giving pharmacists a framework for counseling on moderate consumption.

AHA Scientific Statement on Caffeine and Cardiovascular DiseaseAmerican Heart Associationcardiovascular diseasecaffeinecoffeeenergy drinks Cardiology / Anticoagulation

Background Information

Caffeine's cardiovascular effects vary from coffee's benefits to energy drinks' risks.

Understanding caffeine's effects on cardiovascular health is crucial given its widespread consumption globally. Moderate caffeine intake, especially from coffee, is associated with a lower risk of stroke and atrial fibrillation, but high caffeine doses found in energy drinks may pose cardiovascular risks. This guideline helps clarify caffeine's impact on cardiovascular health, highlighting potential benefits of moderate coffee consumption and risks of high-dose caffeine products. Moderate coffee consumption may reduce stroke and atrial fibrillation risks, but high caffeine doses can be harmful.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Marcus GM, Hu FB, van Dam RM, Cornelis MC, Dewland TA, Kang J, Larsson SC, Page RL 2nd, Parekh N, American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology; and Stroke Council

Citation: Marcus GM, Hu FB, van Dam RM, et al. Caffeine and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2026. doi:10.1161/CIR.0000000000001454

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →